VANI — Vivani Medical, Inc.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1266806 ·
Last close
$1.05
Market Cap
$94.71M
52W High
$1.66
52W Low
$0.80
ADV30
250,795
Next earnings
2026-11-12
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -7,532,000 -7,250,000 35,310,000 14,591,000 22,092,000
Jun 2026 0 — -6,874,000 -6,370,000 41,639,000 19,894,000 22,672,000
Mar 2026 0 — -6,817,000 -6,780,000 42,353,000 19,749,000 23,268,000
Dec 2025 0 — -6,810,000 -6,633,000 39,393,000 16,232,000 23,663,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-25,340,000
Investing CF
$-376,000
Financing CF
$37,225,000
CapEx
$-1,199,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.34
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-168,933,000
Inventory
—
Receivables
$305,000
ST Investments
—
EBIT TTM
$-28,033,000
Pretax Income TTM
$-27,033,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -27,556,000 -26,609,000 39,393,000 23,663,000 15,730,000 -24,320,000
Dec 2024 0 -24,677,000 -23,486,000 41,561,000 23,951,000 17,610,000 -20,786,000
Dec 2023 0 -26,965,000 -25,652,000 45,797,000 25,036,000 20,761,000 -23,699,000
Dec 2022 0 -21,241,000 -13,889,000 51,130,000 6,822,000 44,308,000 -18,787,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-26,313,000
OpCashFlow TTM
—
Assets (Latest)
$41,639,000
Forward EPS
$-0.35

Max Pain — expiry 2027-02-19

max pain strike: $1.00 · spot: $1.05 · call oi: 1,513 · put oi: 2
Expected Move to 2027-02-19: ±$0.48 (45.71%) — implied range $0.57 – $1.53 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NYXH Nyxoah SA $91.65M $0.90 —
SKIN SkinHealth Systems Inc. $90.40M $13.88 —
STIM Neuronetics, Inc. $99.49M $1.28 —
STXS Stereotaxis, Inc. $88.39M $0.88 —
APYX Apyx Medical Corp $107.63M $2.56 —

News headlines (Yahoo Finance, 1h cache)

Vivani Medical Announces Private Placement Equity Financing
2026-11-16 10:30 · Yahoo
Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subj
2026-11-12 13:00 · Yahoo
Vivani Medical: Q3 Earnings Snapshot
2026-11-11 21:20 · Yahoo
Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-11 21:05 · Yahoo
Vivani Medical Announces Participation in Upcoming Investor Conferences
2026-10-12 11:00 · Yahoo
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
2026-08-06 12:00 · Yahoo
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
2026-07-15 23:02 · Yahoo
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
2026-07-14 20:03 · Yahoo
Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant
2026-07-08 11:11 · Yahoo
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
2026-07-07 11:35 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-16 8:00:18 2026-11-13 Williams Gregg Dir, 10% P - Purchase 0.99 48100 47763